Shares of Livongo Health (NASDAQ:LVGO) have been given an average recommendation of “Buy” by the twelve brokerages that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $44.30.
A number of equities research analysts have weighed in on LVGO shares. ValuEngine downgraded Livongo Health from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Zacks Investment Research cut shares of Livongo Health from a “buy” rating to a “hold” rating in a research note on Wednesday, January 8th. Piper Jaffray Companies lifted their target price on shares of Livongo Health from $40.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $46.00 target price on shares of Livongo Health in a research note on Monday, December 16th.
In related news, Director Christopher Bischoff acquired 4,000 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was purchased at an average price of $25.48 per share, for a total transaction of $101,920.00. Following the transaction, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $101,920. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
LVGO stock traded down $0.54 during trading on Thursday, reaching $30.36. 18,288 shares of the stock were exchanged, compared to its average volume of 708,570. Livongo Health has a twelve month low of $15.12 and a twelve month high of $45.68. The business’s 50 day simple moving average is $26.64.
Livongo Health (NASDAQ:LVGO) last released its earnings results on Wednesday, November 6th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.23. The business had revenue of $46.70 million for the quarter, compared to the consensus estimate of $42.77 million. Livongo Health had a negative return on equity of 119.92% and a negative net margin of 43.59%. The firm’s revenue for the quarter was up 148.7% compared to the same quarter last year. During the same period last year, the business earned ($0.55) earnings per share. Research analysts predict that Livongo Health will post -1.38 EPS for the current fiscal year.
Livongo Health Company Profile
Livongo Health, Inc provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications.
Further Reading: How is the LIBOR rate calculated?
Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.